Provider mix and costs associated with treatment of patients with bone metastases secondary to prostate cancer. This is an ASCO Meeting Abstract from the 2012 ASCO Annual Meeting I. This abstract does ...

Until improvements under development can be broadly implemented, routine confirmatory testing in active surveillance for ...

MRI does not reliably exclude clinically significant prostate cancer in about one quarter of patients receiving active surveillance, confirming that MRI is not a substitute for biopsy.

Multiparametric MRI detects more local recurrences after prostatectomy than prostate-specific membrane antigen PET-CT, with the two showing only moderate agreement.

Omitting biopsy in patients with a negative prostate MRI more than halves the diagnoses of clinically insignificant prostate cancer. Detection of clinically insignificant ISUP grade group 1 prostate ...

MRI-based prostate cancer screening of the general population does not increase detection of clinically significant prostate cancer, but it does improve the benefit-vs-harm profile of PSA testing ...

In a recent study published in Scientific Reports, a group of researchers investigated the differences in prostate magnetic resonance imaging (MRI) findings and clinical characteristics between ...

Prostate cancer is the second-leading cause of cancer deaths in American men. Further, non-Hispanic Blacks have a higher incidence of prostate cancer and are more likely to die from it than are ...

AI-driven MRI analysis offers new insights into prostate cancer prognosis, accurately predicting metastasis risk and treatment outcomes for improved patient care. Study: AI-derived Tumor Volume from ...

AI detects prostate cancer more often than radiologists. Additionally, AI triggers false alarms half as often. This is shown by an international study coordinated by Radboud university medical center ...